Replies to post #170213 on Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

"Cellceutix is now in a Phase 2 trial for Brilacidin for the prevention of oral mucositis in patients with head and neck cancer. Should the study show immunomodulatory and anti-inflammatory activity, Brilacidin will be advanced for the indications of ulcerative colitis and hidradenitis suppurativa."

http://www.cellceutix.com/press-release/2016/11/16/cellceutix-requesting-meeting-with-fda-on-kevetrin-for-pediatric-retinoblastoma

"We have also identified inflammatory gastrointestinal disease (ulcerative proctitis) and inflammatory skin disease (hidradenitis suppurativa) as indications for treatment with Brilacidin or our other HDP mimics. The Company is preparing to advance these programs upon review of preliminary results in the oral mucositis trial."

http://www.cellceutix.com/press-release/2016/11/16/cellceutix-files-form-10-q-quarter-ended-september-30-2015

5/26/2015: B-OM started
8/23/2015: First PR in this post
11/10/2015: Second PR in this post
6/15/2016: B-UP started

CTIX had almost one year to review the patients reports between the start of B-OM and B-UP.

Link to source? Interested especially in the "made it clear" part.